{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:08:01Z","timestamp":1791094081293,"version":"4.1.0"},"reference-count":70,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T00:00:00Z","timestamp":1361836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T00:00:00Z","timestamp":1361836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1111\/jcpt.12030","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T12:43:41Z","timestamp":1361882621000},"page":"89-96","source":"Crossref","is-referenced-by-count":20,"title":["The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults"],"prefix":"10.1155","volume":"38","author":[{"given":"Ryan P.","family":"Moenster","sequence":"first","affiliation":[{"name":"St. Louis VA Medical Center - John Cochran Division; St. Louis College of Pharmacy; St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis W.","family":"Linneman","sequence":"additional","affiliation":[{"name":"St. Louis VA Medical Center - John Cochran Division; St. Louis College of Pharmacy; St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Call","sequence":"additional","affiliation":[{"name":"St. Louis VA Medical Center - John Cochran Division; St. Louis College of Pharmacy; St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad L.","family":"Kay","sequence":"additional","affiliation":[{"name":"St. Louis VA Medical Center - John Cochran Division; St. Louis College of Pharmacy; St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"McEvoy","sequence":"additional","affiliation":[{"name":"St. Louis VA Medical Center - John Cochran Division; St. Louis College of Pharmacy; St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Sanders","sequence":"additional","affiliation":[{"name":"St. Louis VA Medical Center - John Cochran Division; St. Louis College of Pharmacy; St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2013,2,26]]},"reference":[{"key":"10.1111\/jcpt.12030-BIB0001|jcpt12030-cit-0001","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1086\/424846","article-title":"Diagnosis and treatment of diabetic foot infections","volume":"39","author":"Lipsky","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12030-BIB0002|jcpt12030-cit-0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.blo.0000088564.81746.62","article-title":"A clinical staging system for adult osteomyelitis","volume":"414","author":"Cierny","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.1111\/jcpt.12030-BIB0003|jcpt12030-cit-0003","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJM199704033361406","article-title":"Osteomyelitis","volume":"336","author":"Lew","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12030-BIB0004|jcpt12030-cit-0004","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1464-5491.2009.02714.x","article-title":"Are diabetic foot ulcers complicated by MRSA osteomyelitis associated with worse prognosis?","volume":"26","author":"Aragon-Sanchez","year":"2009","journal-title":"Diabet Med"},{"key":"10.1111\/jcpt.12030-BIB0005|jcpt12030-cit-0005","first-page":"1027","article-title":"Diagnosis and management of osteomyelitis","volume":"84","author":"Hatzenbuehler","year":"2011","journal-title":"Am Fam Physician"},{"key":"10.1111\/jcpt.12030-BIB0006|jcpt12030-cit-0006","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Disease Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1111\/jcpt.12030-BIB0007|jcpt12030-cit-0007","volume-title":"Vancomycin","author":"Product information","year":"2010"},{"key":"10.1111\/jcpt.12030-BIB0008|jcpt12030-cit-0008","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/0003088-200847120-00004","article-title":"Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia","volume":"47","author":"Garazzino","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12030-BIB0009|jcpt12030-cit-0009","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1185\/030079905X74961","article-title":"Use of daptomycin to treat drug-resistant gram-positive bone and joint infections","volume":"21","author":"Finney","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/jcpt.12030-BIB0010|jcpt12030-cit-0010","volume-title":"Zyvox (linezolid)","author":"Product information","year":"2010"},{"key":"10.1111\/jcpt.12030-BIB0011|jcpt12030-cit-0011","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.clinthera.2006.08.001","article-title":"Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study","volume":"28","author":"Senneville","year":"2006","journal-title":"Clin Ther"},{"key":"10.1111\/jcpt.12030-BIB0012|jcpt12030-cit-0012","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1086\/503839","article-title":"Serotonin toxicity associated with the use of linezolid: a review of postmarketing data","volume":"42","author":"Lawrence","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12030-BIB0013|jcpt12030-cit-0013","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s00586-010-1548-x","article-title":"Penetration of linezolid into rabbit intervertebral discs and surrounding tissues","volume":"19","author":"Komatsu","year":"2010","journal-title":"Eur Spine J"},{"key":"10.1111\/jcpt.12030-BIB0014|jcpt12030-cit-0014","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijantimicag.2007.01.012","article-title":"Penetration of linezolid into sternal bone of patients undergoing cardiopulmonary bypass surgery","volume":"29","author":"Metallidis","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/jcpt.12030-BIB0015|jcpt12030-cit-0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijantimicag.2010.03.007","article-title":"Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections","volume":"36","author":"Traunm\u00fcller","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/jcpt.12030-BIB0016|jcpt12030-cit-0016","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1128\/AAC.47.12.3964-3966.2003","article-title":"Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci","volume":"47","author":"Kutscha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12030-BIB0017|jcpt12030-cit-0017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/dkf066","article-title":"Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement","volume":"50","author":"Lovering","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0018|jcpt12030-cit-0018","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jac\/dkf207","article-title":"Linezolid penetration into osteo-articular tissues","volume":"50","author":"Rana","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0019|jcpt12030-cit-0019","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000317752","article-title":"Compassionate use of linezolid for adult Taiwanese patients with bone and joint infections","volume":"56","author":"Lu","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1111\/jcpt.12030-BIB0020|jcpt12030-cit-0020","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/jac\/dkq281","article-title":"Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia","volume":"65","author":"Legout","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0021|jcpt12030-cit-0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2007.04.006","article-title":"Efficacy and safety of linezolid for gram-positive orthopedic infections: a prospective case series","volume":"59","author":"Rao","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/jcpt.12030-BIB0022|jcpt12030-cit-0022","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1179\/joc.2005.17.6.643","article-title":"The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis","volume":"17","author":"Aneziokoro","year":"2005","journal-title":"J Chemother"},{"key":"10.1111\/jcpt.12030-BIB0023|jcpt12030-cit-0023","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jac\/dki016","article-title":"Linezolid in the treatment of gram-positive prosthetic joint infections","volume":"55","author":"Bassetti","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0024|jcpt12030-cit-0024","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12030-BIB0025|jcpt12030-cit-0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.blo.0000144860.11193.5e","article-title":"Successful treatment of chronic bone and joint infections with oral linezolid","volume":"427","author":"Rao","year":"2004","journal-title":"Clin Orthop Relat Res"},{"key":"10.1111\/jcpt.12030-BIB0026|jcpt12030-cit-0026","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s15010-004-3029-9","article-title":"Linezolid in the treatment of osteomyelitis: results of compassionate use experience","volume":"32","author":"Rayner","year":"2004","journal-title":"Infection"},{"key":"10.1111\/jcpt.12030-BIB0027|jcpt12030-cit-0027","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0025-6196(11)62596-2","article-title":"Linezolid therapy for orthopedic infections","volume":"79","author":"Razonable","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/jcpt.12030-BIB0028|jcpt12030-cit-0028","volume-title":"Cubicin (daptomycin)","author":"Product information","year":"2010"},{"key":"10.1111\/jcpt.12030-BIB0029|jcpt12030-cit-0029","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00402-008-0772-x","article-title":"Daptomycin in bone and joint infections: a review of the literature","volume":"129","author":"Rice","year":"2009","journal-title":"Arch Orthop Trauma Surg"},{"key":"10.1111\/jcpt.12030-BIB0030|jcpt12030-cit-0030","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","article-title":"Once-daily dosing in dogs optimizes daptomycin safety","volume":"44","author":"Oleson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12030-BIB0031|jcpt12030-cit-0031","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in creatine phosphokinase levels: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12030-BIB0032|jcpt12030-cit-0032","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12030-BIB0033|jcpt12030-cit-0033","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1345\/aph.1M085","article-title":"Safety and clinical outocmes when utilizing high-dose (>\/=\u00a08\u00a0mg\/kg) daptomycin therapy","volume":"43","author":"Moise","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jcpt.12030-BIB0034|jcpt12030-cit-0034","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.33.5.689","article-title":"Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits","volume":"33","author":"Mader","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12030-BIB0035|jcpt12030-cit-0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/dkm437","article-title":"Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteremia","volume":"61","author":"Lalani","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0036|jcpt12030-cit-0036","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.spinee.2008.11.008","article-title":"Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine","volume":"9","author":"Burdette","year":"2011","journal-title":"Spine J"},{"key":"10.1111\/jcpt.12030-BIB0037|jcpt12030-cit-0037","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.amjmed.2007.07.008","article-title":"Cubist outcomes registry and experience (CORE) methodology","volume":"120","author":"Rolston","year":"2007","journal-title":"Am J Med"},{"key":"10.1111\/jcpt.12030-BIB0038|jcpt12030-cit-0038","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.amjmed.2007.07.010","article-title":"Clinical experience with daptomycin for the treatment of patients with osteomyelitis","volume":"120","author":"Lamp","year":"2007","journal-title":"Am J Med"},{"key":"10.1111\/jcpt.12030-BIB0039|jcpt12030-cit-0039","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jac\/dkq528","article-title":"Clinical experience with daptomycin in Europe: the first 2.5\u00a0years","volume":"66","author":"Gonzalez-Ruiz","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0040|jcpt12030-cit-0040","volume-title":"Tygacil (tigecycline)","author":"Product information","year":"2011"},{"key":"10.1111\/jcpt.12030-BIB0041|jcpt12030-cit-0041","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.26.8.1099","article-title":"Tigecycline: first of a new class of antimicrobial agents","volume":"26","author":"Rose","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12030-BIB0042|jcpt12030-cit-0042","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dki248","article-title":"Tigecycline","volume":"56","author":"Pankey","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0043|jcpt12030-cit-0043","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/11317100-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of tigecycline","volume":"48","author":"Barbour","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jcpt.12030-BIB0044|jcpt12030-cit-0044","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1469-0691.2007.01933.x","article-title":"New antimicrobial agents for the treatment of gram-positive bacterial infections","volume":"14","author":"Aksoy","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/jcpt.12030-BIB0045|jcpt12030-cit-0045","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1086\/505494","article-title":"Tigecycline: a critical analysis","volume":"43","author":"Stein","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12030-BIB0046|jcpt12030-cit-0046","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0047|jcpt12030-cit-0047","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dki109","article-title":"Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistance Staphylococcus aureus experimental osteomyelitis in a rabbit model","volume":"55","author":"Yin","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0048|jcpt12030-cit-0048","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkl403","article-title":"Serum, tissue, and body fluid concentrations of tigecycline after a single 100\u00a0mg dose","volume":"58","author":"Rodvold","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0049|jcpt12030-cit-0049","volume-title":"Paper presented at 46th annual interscience conference on antimicrobial agents and chemotherapy","author":"Breukink","year":"2006"},{"key":"10.1111\/jcpt.12030-BIB0050|jcpt12030-cit-0050","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2146\/ajhp070080","article-title":"Telavancin: a novel lipoglycopeptide antimicrobial agent","volume":"64","author":"Attwood","year":"2007","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1111\/jcpt.12030-BIB0051|jcpt12030-cit-0051","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dkh156","article-title":"Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration dependent anti-infective with multiple mechanisms of action against gram positive bacteria","volume":"53","author":"King","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0052|jcpt12030-cit-0052","volume-title":"Paper presented at 46th annual interscience conference on antimicrobial agents and chemotherapy","author":"Draghi","year":"2006"},{"key":"10.1111\/jcpt.12030-BIB0053|jcpt12030-cit-0053","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkl235","article-title":"Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus","volume":"58","author":"Leuthner","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0054|jcpt12030-cit-0054","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1128\/AAC.47.11.3602-3604.2003","article-title":"In vitro activity of TD-6424 against Staphylococcus aureus","volume":"47","author":"Pace","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12030-BIB0055|jcpt12030-cit-0055","volume-title":"Paper presented at 46th annual interscience conference on antimicrobial agents and chemotherapy","author":"Thornsberry","year":"2006"},{"key":"10.1111\/jcpt.12030-BIB0056|jcpt12030-cit-0056","volume-title":"Vibativ (telavancin)","author":"Product information","year":"2009"},{"key":"10.1111\/jcpt.12030-BIB0057|jcpt12030-cit-0057","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jac\/dkn490","article-title":"Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model","volume":"63","author":"Yin","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0058|jcpt12030-cit-0058","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/jac\/dkr329","article-title":"Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis","volume":"66","author":"Twilla","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0059|jcpt12030-cit-0059","volume-title":"Teflaro (ceftaroline)","author":"Product information","year":"2011"},{"key":"10.1111\/jcpt.12030-BIB0060|jcpt12030-cit-0060","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12030-BIB0061|jcpt12030-cit-0061","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.30.4.375","article-title":"Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens","volume":"30","author":"Steed","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12030-BIB0062|jcpt12030-cit-0062","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1128\/AAC.00590-07","article-title":"Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections","volume":"51","author":"Talbot","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12030-BIB0063|jcpt12030-cit-0063","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/jac\/dkq193","article-title":"Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis","volume":"65","author":"Jacqueline","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0064|jcpt12030-cit-0064","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12030-BIB0065|jcpt12030-cit-0065","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0066|jcpt12030-cit-0066","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/jac\/dkq109","article-title":"Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections","volume":"65","author":"Traunmuller","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/jcpt.12030-BIB0067|jcpt12030-cit-0067","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12030-BIB0068|jcpt12030-cit-0068","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.diagmicrobio.2005.05.006","article-title":"Pharmacokinetic\/pharmacodynamic profile for tigecycline - a new glycylcycline antimicrobial agent","volume":"52","author":"Meagher","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/jcpt.12030-BIB0069|jcpt12030-cit-0069","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1128\/AAC.00933-10","article-title":"Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection","volume":"55","author":"MacGowan","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/jcpt.12030-BIB0070|jcpt12030-cit-0070","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/jac\/dkr110","article-title":"Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus, and vancomycin-resistant S. aureus using an in vitro model","volume":"66","author":"Zhanel","year":"2011","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12030","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12030","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12030\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:48Z","timestamp":1671818688000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,26]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12030","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,26]]}}}